Metabolic syndrome and intestinal microflora: what is in common?
PDF (Русский)
DOCX

Keywords

intestinal microflora, metabolic syndrome, diabetes, obesity, probiotics

How to Cite

PlotnikovаE. Y. (2016). Metabolic syndrome and intestinal microflora: what is in common?. Herald of Pancreatic Club, 31(2), 63-72. https://doi.org/10.33149/vkp.2016.02.10

Abstract views: 11
PDF Downloads: 33 PDF Downloads: 19

Abstract

The article highlights the problem of the correlation between human intestinal microbiome and metabolic syndrome. Changes in bacterial intestinal proportions upon obesity captured the attention of scientists around the world, especially in relation to their effect on the metabolism. Increasing proportion of Firmicutes and Actinobacteria and decrease of Bacteroidetes are associated with increased levels of serum lipopolysaccharides, insulin resistance, weight gain, and other co-morbid manifestations of the metabolic syndrome. The mechanisms, underlying this interdisciplinary problem, are actively studied to optimize the prevention and treatment of obesity and type 2 diabetes.

https://doi.org/10.33149/vkp.2016.02.10
PDF (Русский)
DOCX

References

1. Некоторые аспекты диагностики и лечения избыточной бактериальной контаминации тонкой кишки в клинической практике / Е. Ю. Плотникова, М. В. Борщ, М. В. Краснова, Е. Н. Баранова // Лечащий врач. – 2013. – № 2. – С. 52–56.
2. Alberti K. G. Definition, diagnosis and classification of diabetes mellitus and its complications. Part : diagnosis and classification of diabetes mellitus provisional report of a WHO consultation / K. G. Alberti, P. Z. Zimmet // Diabet Med. – 1998. – Vol. 15. – P. 539–553.
3. Alberti K. G. The metabolic syndrome : a new worldwide definition / K. G. Alberti, P. Zimmet, J. Shaw // Lancet. – 2005. – Vol. 366. – P. 1059–1062.
4. Alcock J. Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms / J. Alcock, C. C. Maley, C. A. Aktipis // BioEssays. – 2014. – Vol. 36, No 10. – P. 940–949.
5. An obesity-associated gut microbiome with increased capacity for energy harvest / P. J. Turnbaugh, R. E. Ley, M. A. Mahowald [et al.] // Nature. – 2006. – Vol. 444, No 7122. – P. 1027–1038.
6. Bacterial community variation in human body habitats across space and time / E. K. Costello, C. L. Lauber, M. Hamady [et аl.] // Science. – 2009. – Vol. 326. – P. 1694–1697.
7. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut / A. Bezkorovainy // Am. J. Clin. Nutr. – 2001. – Vol. 73, No 2. – P. 399S–405S.
8. Bifidobacterium animalis AHC7 protects against pathogen-induced NF-kappaB activation in vivo / D. O’Mahony, S. Murphy, T. Boileau [et al.] // BMC Immuno. – 2010. – Vol. 11. – P. 63.
9. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms / H. V. Lin, A. Frassetto, E. J. Kowalik [et al.] // PLoS One. – 2012. – Vol. 7, No 4. – P. e35240.
10. Changes in dominant groups of the gut microbiota do not explain cereal-fiber induced improvement of whole-body insulin sensitivity / M. O. Weickert, A. M. Arafat, M. Blaut [et al.] // Nutr. Metab. – 2011. – Vol. 8. – P. 90.
11. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice / P. D. Cani, R. Bibiloni, C. Knauf [et al.] // Diabetes. – 2008. – Vol. 57. – P. 1470–1481.
12. Cuche G. Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway / G. Cuche, J. C. Cuber, C. H. Malbert // Am. J. Physiol. Gastrointest. Liver Physiol. – 2000. – Vol. 279, No 5. – P. G925–930.
13. Darzi J. Do SCFA have a role in appetite regulation? / J. Darzi, G. S. Frost, M. Robertson // Proc. Nutr. Soc. – 2011. – Vol. 70, No 1. – P. 119–128.
14. Dasu M. R. Toll-like receptors and diabetes: a therapeutic perspective / M. R. Dasu, S. Ramirez, R. R. Isseroff // Clin. Sci. – 2012. – Vol. 122, No 5. – P. 203–214.
15. Development of the human infant intestinal microbiota / C. Palmer, E. M. Bik, D. B. DiGiulio [et al.] // PLoS Biol. – 2007. – Vol. 5. – P. e177.
16. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans / B. D. Muegge, J. Kuczynski, D. Knights [et al.] // Science. – 2011. – Vol. 332. – P. 970–974.
17. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers / J. P. Furet, L. C. Kong, J. Tap [et al.] // Diabetes. – 2010. – Vol. 59. – P. 3049–3057.
18. Diversity of the human intestinal microbial flora / P. B. Eckburg, E. M. Bik, C. N. Bernstein [et al.] // Science. – 2005. – Vol. 308. – P. 1635–1638.
19. Early differences in fecal microbiota composition in children may predict overweight / M. Kalliomaki, M. C. Collado, S. Salminen, E. Isolauri // Am. J. Clin. Nutr. – 2008. – Vol. 87. – P. 534–538.
20. Effects of long-term soluble vs. insoluble dietary fiber intake on high-fat diet-induced obesity in C57BL/6J mice / F. Isken, S. Klaus, M. Osterhoff [et al.] // J. Nutr. Biochem. – 2010. – Vol. 21. – P. 278–284.
21. Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans / M. O. Weickert, M. Roden, F. Isken, D. Hoffmann [et al.] // Am. J. Clin. Nutr. – 2011. – Vol. 94. – P. 459–471.
22. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41 / B. S. Samuel, A. Shaito, T. Motoike [et al.] // Proc. Natl. Acad. Sci. USA. – 2008. – Vol. 105, No 43. – P. 16767–17210.
23. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes / M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin [et al.] // J. Immunol. – 2011. – Vol. 186. – P. 1162–1172.
24. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes / U. Ozcan, Q. Cao, E. Yilmaz [et al.] // Science. – 2004. – Vol. 306. – P. 457–461.
25. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans / R. Jumpertz, D. S. Le, P. J. Turnbaugh [et al.] // Am. J. Clin. Nutr. – 2011. – Vol. 94, No 1. – P. 58–65.
26. Evolution of mammals and their gut microbes / R. E. Ley, M. Hamady, C. Lozupone [et al.] // Science. – 2008. – Vol. 320. – P. 1647–1651.
27. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice / A. M. Caricilli, P. K. Picardi, L. L. de Abreu [et al.] // PLoS Biol. 2011. – Vol. 9. – P. e1001212.
28. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice / M. Membrez, F. Blancher, M. Jaquet [et al.] // FASEB. – 2008. – Vol. 22. – P. 2416–2426.
29. Gut microbiota: the neglected endocrine organ / G. Clarke, R. M. Stilling, P. J. Kennedy [et al.] // Mol. Endocrinolme. – 2014. – Vol. 1. – P. 108.
30. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth / E. Scarpellini, M. Gabrielli, C. E. Lauritano [et al.] // Aliment. Pharmacol. Ther. – 2007. – Vol. 25, No 7. – P. 781–786.
31. Hill J. O. Understanding and addressing the epidemic of obesity: an energy balance perspective / J. O. Hill // Endocr. Rev. – 2006. – Vol. 27. – P. 750–761.
32. Hopkins M. J. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles / M. J. Hopkins, R. Sharp, G. T. MacFarlane // Gut. – 2001. – Vol. 48. – P. 198–205.
33. Host-bacterial mutualism in the human intestine / F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, J. I. Gordon // Science. – 2005. – Vol. 307. – P. 1915–1920.
34. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice / H. Y. Lee, J. H. Park, S. H. Seok [et al.] // Biochim. Biophys. Acta. – 2006. – Vol. 1761. – P. 736–744.
35. Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans / A. Monroy, S. Kamath, A. O. Chavez [et al.] // Diabetologia. – 2009. – Vol. 52. – P. 2169–2181.
36. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet / M. Bjursell, T. Admyre, M. Göransson [et al.] // Am. J. Physiol. Endocrinol. Metab. – 2011. – Vol. 300, No 1. – P. E11–20.
37. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast / A. C. Nilsson, E. M. Ostman, J. J. Holst, I. M. Björck // J. Nutr. 2008. – Vol. 138. – P. 732–739.
38. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis / R. A. Koeth, Z. Wang, B. S. Levison [et al.] // Nat. Med. – 2013. – Vol. 19. – P. 576–585.
39. Karra E. The role of peptide YY in appetite regulation and obesity / E. Karra, K. Chandarana, R. L. Batterham // J. Physiol. – 2009. – Vol. 587, Pt 1. – P. 19–25.
40. Kim D. Y. Serotonin: a mediator of the brain-gut connection / D. Y. Kim, M. Camilleri // Am. J. Gastroenterol. – 2000. – Vol. 95. – P. 2698–2709.
41. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy / S. Devaraj, P. Tobias, B. S. Kasinath, R. Ramsamooj [et al.] // Arterioscler. Thromb. Vasc. Biol. – 2011. – Vol. 31. – P. 1796–804.
42. Korner J. To eat or not to eat – how the gut talks to the brain / J. Korner, R. I. Leibe // N. Engl. J. Med. –2003. – Vol. 349. – P. 926–928.
43. Linking long-term dietary patterns with gut microbial enterotypes / G. D. Wu, J. Chen, C. Hoffmann [et al.] // Science. – 2011. – Vol. 334. – P. 105–108.
44. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics / M. Lyte // BioEssays. – 2011. – Vol. 33. – P. 574–581.
45. Mackie R. I. Developmental microbial ecology of the neonatal gastrointestinal tract / R. I. Mackie, A. Sghir, H. R. Gaskins // Am. J. Clin. Nutr. – 1999. – Vol. 69. – P. 1035S–1045S.
46. Madsen K. I. The use ofprobiotics in gastrointestinal disease / K. I. Madsen // Can. J. Gastroenterol. – 2001. – Vol. 15, No 12. – P. 817–822.
47. Management of metabolic syndrome through probiotic and prebiotic interventions / H. M. Rashmi, R. Namita [et al.] // Indian J. Endocrinol. Metab. – 2012. – Vol. 16, No 1. – P. 20–27.
48. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice / F. Bäckhed, J. K. Manchester, C. F. Semenkovich, J. I. Gordon // Proc. Natl. Acad. Sci. USA. – 2007. – Vol. 104, No 3. – P. 979–984.
49. Meta HIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing / J. Qin, R. Li, J. Raes [et al.] // Nature. – 2010. – Vol. 464. – P. 59–65.
50. Metabolic endotoxemia initiates obesity and insulin resistance / P. D. Cani, J. Amar, M. A. Iglesias [et al.] // Diabetes. – 2007. – Vol. 56. – P. 1761–1772.
51. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5 / M. Vijay-Kumar, J. D. Aitken, F. A. Carvalho [et al.] // Science. – 2010. – Vol. 328, No 5975. – P. 228–3110.
52. Microbial ecology: human gut microbes associated with obesity / R. E. Ley, P. J. Turnbaugh, S. Klein, J. I.Gordon // Nature. – 2006. – Vol. 444. – P. 1022–1023.
53. Microbiota and SCFA in lean and overweight healthy subjects / A. Schwiertz, D. Taras, K. Schafer [et al.] // Obesity (SilverSpring). – 2010. – Vol. 18. – P. 190–195.
54. Molecular characterisation of the faecal microbiota in patients with type II diabetes / X. Wu, C. Ma, L. Han [et al.] // Curr. Microbiol. – 2010. – Vol. 61. – P. 69–78.
55. Molecular mechanisms of insulin resistance / S. Schinner, W. A. Scherbaum, S. R. Bornstein, A. Barthel // Diabet. Med. – 2005. – Vol. 22. – P. 674–682.
56. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy / M. Baraldi, R. Avallone, L. Corsi [et al.] // Metab. Brain Dis. – 2009. – Vol. 24. – P. 81–93.
57. O’Hara A. M. The gut flora as a forgotten organ / A. M. O’Hara, F. Shanahan // EMBO Rep. – 2006. – Vol. 7. – P. 688–693.
58. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? / L. Conterno, F. Fava, R. Viola, K. M. Tuohy // Genes Nutr. – 2011. – Vol. 6, No 3. – P. 241–260.
59. Ouwehand A. The role of the intestinal microflora for the development of the immune system in early childhood / A. Ouwehand, E. Isolauri, S. Salminen // Eur. J. Nutr. – 2002. – Vol. 41. – P. 132–137.
60. Parnell J. A. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults / J. A. Parnell, R. A. Reimer // Am. J. Clin. Nutr. – 2009. – Vol. 89. – P. 1751–1759.
61. Peripheral neural targets in obesity / A. J. Page, E. Symonds, M. Peiris [et al.] // Br. J. Pharmacol. – 2012. – Vol. 166, No 5. – P. 1537–5810.
62. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans / B. C. Field, A. M. Wren, V. Peters [et al.] // Diabetes. – 2010. – Vol. 59, No 7. – P. 1635–1910.
63. Rastmaneh R. High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction / R. Rastmaneh // Chem. Biol. Interact. – 2011. – Vol. 189. – P. 1–8.
64. Reduced energy intake at breakfast is not compensated for at lunch if a high-insoluble-fiber cereal replaces a low-fiber cereal / A. Hamedani, T. Akhavan, R. A. Samra, G. H. Anderson // Am. J. Clin. Nutr. – 2009. – Vol. 89. – P. 1343–1349.
65. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial / Y. Kadooka, M. Sato, K. Imaizumi [et al.] // Eur. J. Clin. Nutr. – 2010. – Vol. 64. – P. 636–643.
66. Rhee S. H. Basic and translational understandings of microbial recognition by toll-like receptors in the intestine / S. Rhee // J. Neurogastroenterol. Motil. – 2011. – Vol. 17, No 1. – P. 28–34.
67. Saavedra J. M. Clinical applications ofprobiotic agents / J. M. Saavedra // Am. J. Clin. Nutr. – 2001. – Vol. 73, No 6. – P. 1147S–1151S.
68. Samuel B. S. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism / B. S. Samuel, J. I. Gordon // Proc. Natl. Acad. Sci. USA. – 2006. – Vol. 103, No 26. – P. 10011–10610.
69. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia / P. D. Cani, A. M. Neyrinck, F. Fava [et al.] // Diabetologia. – 2007. – Vol. 50. – P. 2374–2383.
70. Sepsis Associated With Probiotic Therapy Lactobacillus / M. H. Land, K. Rouster–Stevens, C. R. Woods [et al.] // Pediatrics. – 2005. – Vol. 115. – P. 178–181.
71. Shen J. The gut microbiota, obesity and insulin resistance / J. Shen, M. S. Obin, L. Zhao // Mol. Aspects Med. – 2013. – Vol. 34, No 1. – P. 39–58.
72. Sommer F, Bäckhed F. The gut microbiota – masters of host development and physiology / Sommer F, Bäckhed F. // Nat. Rev. Microbiol. – 2013. – Vol. 11. – P. 227–238.
73. Substantial production of dopamine in the human gastrointestinal tract / Eisenhofer G, Aneman A, Friberg P, Hooper D [et al.] // J. Clin. Endocrinol. Metab. – 1997. – Vol. 82. – P. 3864–3871.
74. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes / J. J. Senn, P. J. Klover, I. A. Nowak [et al.] // J. Biol. Chem. – 2003. – Vol. 278. – P. 13740–13746.
75. The effect of a probiotic on hepatic steatosis / S. F. Solga, G. Buckley, J. M. Clark [et al.] // J. Clin. Gastroenterol. – 2008. – Vol. 42. – P. 1117–1119.
76. The gut microbiota as an environmental factor that regulates fat storage / F. Bäckhed, H. Ding, T. Wang [et al.] // Proc. Natl. Acad. Sci. USA. – 2004. – Vol. 101, No 44. – P. 15718–2310.
77. The host genotype affects the bacterial community in the human gastrointestinal tract / E. G. Zoetendal, A. D. L. Akkermans, W. M. Akkermans-van Vliet [et al.] // Microb. Ecol. Health Dis. – 2001. – Vol. 13. – P. 129–134.
78. The innate immune response to bacterial flagellin is mediated by toll-like receptor-5 / F. Hayashi, K. D. Smith, A. Ozinsky [et al.] // Nature. – 2001. – Vol. 410, No 6832. – P. 1099–10310.
79. The probiotic Lactobacillus gasseri SBT2055 inhibits enlargement of visceral adipocytes and upregulation of serum soluble adhesion molecule (sICAM-1) in rats / Y. Kadooka, A. Ogawa, K. Ikuyama [et al.] // Int. Dairy J. – 2011. – Vol. 30. – P. 1–5.
80. TLR4 links innate immunity and fatty acid–induced insulin resistance / H. Shi, M. V. Kokoeva, K. Inouye [et al.] // J Clin Invest 2006. – Vol. 116. – P. 3015–3025.
81. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells / M. W. Hornef, T. Frisan, A. Vandewalle [et al.] // J. Exp. Med. – 2002. – Vol. 195. – P. 559–570.
82. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome / A. Vrieze, E. Van Nood, F. Holleman [et al.] // Gastroenterology. – 2012. – Vol. 143. – P. 913–917.
83. Tremaroli V. Functional interactions between the gut microbiota and host metabolism / V. Tremaroli, F. Bäckhed // Nature. – 2012. – Vol. 489. – P. 242–249.
84. Vague J. La diff, rentiation sexuelle, facteur d, terminant des formes de l’ob, sit / J. Vague // Presse Med. – 1947. – Vol. 30. – P. 339–340.
85. Winder W. W. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes / W. W. Winder, D. G. Hardie // Am. J. Physiol. – 1999. – Vol. 277, No 1. – P. E1–10.